中国ST11耐碳青霉烯类肺炎克雷伯菌耐药分子机制研究进展  

Research progress on the molecular mechanism of drug resistance in carbapenem-resistant Klebsiella pneumoniae ST11 in China

作　　者：唐依莲 张晨(综述) 蒲翔(审校) TANG Yilian;ZHANG Chen;PU Xiang(Guizhou University of Traditional Chinese Medicine,Guiyang,Guizhou 550025,China)

机构地区：[1]贵州中医药大学,贵州贵阳550025

出　　处：《检验医学与临床》2023年第11期1606-1610,共5页Laboratory Medicine and Clinic

基　　金：国家自然科学基金项目(8260913)。

摘　　要：序列型11(ST11)耐碳青霉烯类肺炎克雷伯菌(CRKP)携带bla产肺炎克雷伯菌碳青霉烯酶-2已广泛分布于世界各地,在中国也频频有文献报道。因为缺乏治疗选择,这些耐多药微生物对几乎所有可用的抗菌药物均具有耐药性,并引起与高发病率和病死率相关的严重感染。在中国,CRKP的大部分传播可归因于产生肺炎克雷伯菌碳青霉烯酶的生物体,其中大部分是由ST11克隆产生的。了解耐药性的分子进化机制及ST11 CRKP在中国的流行情况将有助于控制和预防耐药细菌的出现和暴发。Sequence type 11(ST11)carbapenem-resistant klebsiella pneumoniae(CRKP)carrying bla-producing klebsiella pneumoniae carbapenemase-2 has been widely distributed in the world,and it also been frequently reported in China.In the absence of treatment options,these multidrug-resistant organisms are resistant to almost all available antimicrobial drugs and cause severe infections associated with high morbidity and mortality.Much of the spread of CRKP in China can be attributed to organisms producing klebsiella pneumoniae carbapenemases,most of which are produced by the ST11 clone.Understanding the molecular evolution mechanism of drug resistance and the prevalence of ST11 CRKP in China will help to control and prevent the emergence and outbreak of drug-resistant bacteria.

关 键 词：耐碳青霉烯类肺炎克雷伯菌 序列型11 耐药机制 

分 类 号：R446.5[医药卫生—诊断学]